Benzinga · Feb 20, 2026
HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
DW
NASDAQ · DWTX
Dogwood Therapeutics, Inc.
Healthcare · Biotechnology
$1.70
Up+$0.02 (+1.18%)
Updated Sep 18, 2026, 1:03 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 11.96M
- P/E ratio
- -0.31
- Dividend yield
- 0.00%
- 52-week range
- $1.28 – $9.50
- Volume
- 84.28K
- Avg. volume
- 758.26K
Price performance
DWTX price history
1M range · 19 trading sessions · Daily adjusted prices
DWTX closed at $1.70 after 19 trading sessions, down 27.04% for the selected period.
- Last close
- $1.70
- Period change
- -27.04%
- Period low
- $1.70
- Period high
- $2.68
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.80 | $1.84 | $1.67 | $1.70 | 84.28K |
| Sep 15, 2026 | $1.81 | $1.84 | $1.72 | $1.73 | 31.86K |
| Sep 14, 2026 | $1.94 | $2.015 | $1.77 | $1.845 | 121.96K |
| Sep 11, 2026 | $1.88 | $2.00 | $1.83 | $1.94 | 53.08K |
| Sep 10, 2026 | $1.94 | $1.95 | $1.83 | $1.88 | 40.61K |
| Sep 9, 2026 | $2.125 | $2.15 | $1.895 | $1.94 | 39.26K |
| Sep 8, 2026 | $2.29 | $2.3438 | $2.04 | $2.04 | 85.89K |
| Sep 4, 2026 | $2.37 | $2.38 | $2.2509 | $2.29 | 70.17K |
| Sep 3, 2026 | $2.46 | $2.59 | $2.34 | $2.36 | 46.65K |
| Sep 2, 2026 | $2.60 | $2.66 | $2.45 | $2.48 | 50.42K |
| Sep 1, 2026 | $2.70 | $2.725 | $2.55 | $2.63 | 145.33K |
| Aug 31, 2026 | $2.61 | $2.74 | $2.5352 | $2.58 | 64.36K |
| Aug 28, 2026 | $2.36 | $2.70 | $2.35 | $2.65 | 135.38K |
| Aug 27, 2026 | $2.64 | $2.64 | $2.32 | $2.32 | 69.41K |
| Aug 26, 2026 | $2.70 | $2.80 | $2.60 | $2.66 | 120.58K |
| Aug 25, 2026 | $2.64 | $2.68 | $2.53 | $2.68 | 123.03K |
| Aug 24, 2026 | $2.51 | $2.77 | $2.50 | $2.56 | 101.48K |
| Aug 21, 2026 | $2.31 | $2.5757 | $2.31 | $2.49 | 123.6K |
| Aug 20, 2026 | $2.27 | $2.39 | $2.10 | $2.33 | 59.31K |
Latest DWTX news
The latest Smart Investors Daily articles mentioning DWTX.
Stock researchCompany · Overview
DWTX research
Overview
Company profile and research snapshot.
Company profile
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 27, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 30, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 30, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Feb 2, 2026
DWTX: Financing Secures Funding Through Phase 2b Data Readout
By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Financial Update On January 15, 2026, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5 million in gross proceeds through a registered direct offering and a concurrent private placement. An aggregate of 4,386,037
Yahoo · Feb 2, 2026
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial.
Benzinga · Feb 2, 2026
Dogwood Reaches 50% Enrollment In Ongoing Halneuron Phase 2b Trial
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron® treatment to be well tolerated -
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
